{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:23:01Z","timestamp":1773019381060,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Adequate anticoagulation during catheter ablation (CA) for atrial fibrillation (AF) is crucial for the prevention of both thromboembolic events and life-threatening bleeding. The purpose of this updated meta-analysis is to compare the safety and efficacy of uninterrupted and minimally interrupted periprocedural direct oral anticoagulant (DOAC) protocols and uninterrupted vitamin K antagonist (VKA) therapy in patients undergoing CA for AF based on the latest evidence. Randomized controlled trials, prospective observational studies, and retrospective registries comparing DOACs to VKAs were identified in multiple databases (Embase, MEDLINE via PubMed, CENTRAL, and Scopus). The primary outcomes were stroke or transient ischemic attack (TIA), major bleeding, and net clinical benefit. Forty-two studies with a total of 22,715 patients were included in the final analysis. The occurrence of major bleeding was significantly lower in patients assigned to uninterrupted DOAC treatment compared to VKAs (pooled odds ratio (POR): 0.71, confidence interval (CI): 0.51\u20130.99). The pooled analysis of both uninterrupted and minimally interrupted DOAC groups also showed significant reduction in major bleeding events (POR: 0.70, CI: 0.53\u20130.93). The incidence of thromboembolic events was low, with no significant difference between groups. This updated meta-analysis showed that DOAC therapy is as effective as VKA in preventing stroke and TIA. Minimally interrupted DOAC therapy is a non-inferior periprocedural anticoagulation strategy; however, uninterrupted DOAC therapy showed superiority compared to VKA with regard to major, life-threatening bleeding. Based on our in-depth analysis, we conclude that both DOAC strategies are equally safe and preferable alternatives to VKAs in patients undergoing CA for AF.<\/jats:p>","DOI":"10.3390\/jcm9103073","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T08:33:03Z","timestamp":1600936383000},"page":"3073","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Uninterrupted or Minimally Interrupted Direct Oral Anticoagulant Therapy is a Safe Alternative to Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Meta-Analysis"],"prefix":"10.3390","volume":"9","author":[{"given":"M\u00e1t\u00e9","family":"Ott\u00f3ffy","sequence":"first","affiliation":[{"name":"First Department of Medicine, Division of Cardiology, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"},{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"},{"name":"J\u00e1nos Szent\u00e1gothai Research Center, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"M\u00e1trai","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelli","family":"Farkas","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Czopf","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Division of Cardiology, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2213-4865","authenticated-orcid":false,"given":"Katalin","family":"M\u00e1rta","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"},{"name":"J\u00e1nos Szent\u00e1gothai Research Center, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-0571","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Garami","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"Balask\u00f3","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Em\u0151ke","family":"P\u00f3t\u00f3n\u00e9-Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Mik\u00f3","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Rost\u00e1s","sequence":"additional","affiliation":[{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-1470","authenticated-orcid":false,"given":"Bastian","family":"Wobbe","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Division of Cardiology, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-857X","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Habon","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Division of Cardiology, Medical School, University of P\u00e9cs, 7622 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2013","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.7326\/M13-1467","article-title":"Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review","volume":"160","author":"Lapointe","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacep.2015.11.001","article-title":"Rhythm control versus rate control and clinical outcomes in patients with atrial fibrillation: Results from the ORBIT-AF registry","volume":"2","author":"Noheria","year":"2016","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Lundquist, C.B., Boriani, G., Castella, M., Dan, G.A., and Dilaveris, P. (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J., ehaa612.","DOI":"10.1093\/eurheartj\/ehab648"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.113.003862","article-title":"In-Hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: Analysis of 93,801 procedures","volume":"128","author":"Deshmukh","year":"2013","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/CIRCEP.113.000768","article-title":"Complications of catheter ablation of atrial fibrillation: A systematic review","volume":"6","author":"Gupta","year":"2013","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/europace\/euu007","article-title":"Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation","volume":"16","author":"Marijon","year":"2014","journal-title":"Europace"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/CIRCEP.113.000320","article-title":"Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation","volume":"6","author":"Bassiouny","year":"2013","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/europace\/euu196","article-title":"Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: Comparison of aspirin, warfarin, dabigatran, and rivaroxaban","volume":"16","author":"Winkle","year":"2014","journal-title":"Europace"},{"key":"ref_16","first-page":"278","article-title":"Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation","volume":"49","author":"Armbruster","year":"2015","journal-title":"Ann. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/europace\/euv132","article-title":"Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: Results from the first European Snapshot Survey on procedural routines for atrial fibrillation ablation (ESS-PRAFA)","volume":"17","author":"Potpara","year":"2015","journal-title":"Europace"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e191994","DOI":"10.1001\/jamanetworkopen.2019.1994","article-title":"Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial","volume":"2","author":"Nogami","year":"2019","journal-title":"JAMA Netw. Open."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacep.2018.03.003","article-title":"The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: A systematic review and meta-analysis","volume":"4","author":"Khan","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2019.0693","article-title":"Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial ibrillation: The CABANA Randomized Clinical Trial","volume":"321","author":"Packer","year":"2019","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehw087","article-title":"Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: Data from Swedish health registries","volume":"37","author":"Friberg","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kirchhof, P., Camm, A.J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., Fetsch, T., Van Gelder, I.C., Haase, D., and Haegeli, L.M. (2020). Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2019422"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijcard.2018.03.095","article-title":"Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis","volume":"262","author":"Ha","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hrthm.2017.09.011","article-title":"An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation","volume":"15","author":"Cardoso","year":"2018","journal-title":"Heart Rhythm"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euy133","article-title":"Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Romero","year":"2018","journal-title":"Europace"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euy148","article-title":"Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: A prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events","volume":"21","author":"Nakamura","year":"2018","journal-title":"Europace"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jjcc.2015.10.003","article-title":"Ablation perioperative dabigatran in use envisioning in Japan: The ABRIDGE-J Study Design","volume":"68","author":"Goya","year":"2016","journal-title":"J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jacep.2017.11.005","article-title":"A Prospective randomized trial of apixaban dosing during atrial fibrillation ablation","volume":"4","author":"Reynolds","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/10\/3073\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:13:08Z","timestamp":1760177588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/10\/3073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["jcm9103073"],"URL":"https:\/\/doi.org\/10.3390\/jcm9103073","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}